Root Admin Guide Posted May 25, 2016 Root Admin Report Share Posted May 25, 2016 "Omiganan is a cationic antimicrobial peptide, a first-in-class for rosacea, that is entering into phase 3 trials. In a phase 2 dose-ranging study (N=240),[18] it showed a dose-dependent reduction in inflammatory lesions. The 2.5% formulation resulted in a 40% reduction at week 9. Cutaneous tolerability was good." Hilary Baldwin, MD, What's New in Acne and Rosacea, Medscape Dermatology, April 29, 2016 [last paragraph of the article] Omiganan (CLS001) developed by Cutanea. Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now